A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with
Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is
dose escalation and Part 2 is a Simon 2-Stage design